The Scientific Advisory Board – COSSF

The Comité d’orientation stratégique et scientifique de la filière (COSSF) is the scientific advisory board of MabDesign.

It has 10 permanent experts.

 

  • Alan Beck
  • Alain Beck

    Pierre Fabre

    Senior Director, Biologics CMC & developability of the CIPF, associated editor of mAbs Journal

    read more

  • Paul baduel
  • Paul Baduel

    Sanofi

    Director Pilots and Centres of Excellence, Industrial Operations, Sanofi-Pasteur

    read more

 

  • Christophe De Romeuf
  • Christophe de Romeuf

    LFB Biotechnologies

    Head of Innovative Immunology department at LFB Biotechnologies.

    read more

  • Jean Louis Pinquier
  • Jean-Louis Pinquier

    Medicen

    MD, Chairman of the Translational Medicine committee at MEDICEN, and consultant at DECISIONS R&D Consulting.

    read more

 

  • Jean François Prost
  • Jean-François Prost

    GamaMabs Pharma

    Vice-President R&D and Strategy at GamaMabs Pharma

    read more

  • Jerome Tiollier
  • Jérôme Tiollier

    Our Future Universe

    Chairman, Co-Founder, Our Future Universe

    read more

 

  • Bernard Vanhove
  • Bernard Vanhove

    Xenothera

    Chief Operating Officer

    read more

  • Hervé Watier
  • Hervé Watier

    MAbImprove

    Professor of Immunology at the Faculty of Medicine-Tours & Head of the Lab. of Immunology in the Univ. Hospital of Tours.

    read more

 

  • Nicolas Poirier

    OSE Immunotherapeutics

    Chief Scientific Officer

    read more

  • Stéphanie Cornen
  • Stéphanie Cornen

Innate Pharma

Director, Research and development

read more

 

Alan BeckAlain Beck

Pierre Fabre

Senior Director, Biologics CMC & developability of the CIPF, associated editor of mAbs Journal

 Dr. A. Beck is Senior Director of Analytical Chemistry, New Biological Entities, at the Center of Immunology Pierre Fabre (FR), associated editor of mAbs (USA) and mAbDesign AB chairman (FR). He has contributed to the R&D of immune-oncology mAbs, clinical stages mAbs and ADCs in oncology (dalotuzumab licensed to Merck; telisotuzumab vedotin, licensed to AbbVie and h515H7), peptides and vaccines (RSV, ELA/P40). He has published more than 190 papers and reports on mAbs, biosimilars, biobetters, ADCs, bsAbs, Fc-fusion, protein scaffolds structure/function relationships and developability. He was involved in more than 230 scientific meetings (AIS, ASMS, BAS, CASSS, EAC, HPLC, IBC, IMSC, PEGS, SEP, WADC, WBC) as chairperson, invited keynote speaker, panelist, moderator, advisor, and organizer as well as to meetings and workshops with regulatory agencies (ANSM, EMA, EDQM, FDA, PEI, WHO).

Paul BaduelPaul Baduel

Sanofi

Director Pilots and Centres of Excellence, Industrial Operations, Sanofi-Pasteur

Paul has graduated in biochemical engineering from National Institute of Applied Sciences (Toulouse France) in 1986.  He started his carrier in 1988 as Research Scientist in molecular biology at Rhône-Poulenc Santé in charge of development of processes for production of recombinant proteins.

In the 90’s he was in charge of process development for new antibiotics and contributed to the industrialisation of recombinant process for Vitamin B12. Then he was appointed Project Manager for the development of new semi-synthetic anti-infective. Then Paul was appointed Manager of the Biotechnology department at Rhône-Poulenc Rorer for late stage development compounds and support to commercial products.

From 2000 to 2012 Paul was leading the Process Development Biotechnology Department of Aventis in France, Germany and Italy. In this Position Paul was in charge of support to industrial production and development of recombinant proteins (Insulin), Monoclonal Antibodies, antibiotics, Vitamin and Steroids.

Since 2013, Paul was responsible for Global Technology Innovation within Sanofi-Pasteur, the Vaccine division of Sanofi. He is today in charge of Pilots and Excellence centres for Sanofi Pasteur Industrial Operations.

Christophe de RomeufChristophe de Romeuf

LFB Biotechnologies

Head of Innovative Immunology department at LFB Biotechnologies.

Christophe obtained his PhD degree (1988) in biochemistry then was a postdoctoral fellow in the Jerome Holland  Laboratory Research Center, American Red Cross, Rockville USA.

From 1990 to 1997 at EFS Lille (French Blood center), Christophe was in charge of various topics related to platelet adhesion and primary hemostasis.

In 1998, he moved to the Immunology Research department at LFB Biotechnologies and identified and characterized the anti-Rhesus D monoclonal antibody (hemolytic disease of the newborn) currently in clinical trial. This work evidences that absence of core fucose in the Fc region N-linked glycans of antibodies increases their antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis activity.

From 2001 to 2012 as the head of Immunology department Christophe was in charge of various monoclonal antibody pharmacology studies and more specifically worked on the optimized anti-CD20 TG-1101 (ublituximab) developed by TG Therapeutics USA and  monoclonal antibodies GM102 which targets Anti-Müllerian Human Receptor II (licenced at Gamamabs).

From 2013 to now, Christophe is the group coordinator for the LFB Innovative department in Lille and as head of the Immunology department works with his group on different programs in the field of oncology, auto-immune and infectious diseases.

Jean-Louis Pinquier Jean-Louis Pinquier

MEDICEN

MD, Chairman of the Translational Medicine committee at MEDICEN, and consultant at DECISIONS R&D Consulting.

Jean-Louis Pinquier is a medical doctor, currently Chairman of the Translational Medicine committee at MEDICEN, and consultant at DECISIONS R&D Consulting. Over these past 30 years he has been involved in more than hundred drug development programs from discovery to registration and beyond. He was particularly active in early clinical development, covering multiple therapeutics areas. Since the early 2000s, he was involved in several biologics program including naked and drug conjugate monoclonal antibodies. Up to 2014 he was deputy global head of the Clinical and Exploratory Pharmacology Dept. at Sanofi R&D, and member of Sanofi R&D France Board. After having spent 7 years in Cochin University Hospital as assistant professor and medical director of the Therapeutics Research Institute, he moved to pharmaceutical industry in 1993, first at Synthelabo Research, Sanofi-Synthelabo, and then Aventis and Sanofi-Aventis.

Dr Pinquier is board certified in Clinical Pharmacology, Internal Medicine and Rheumatology and still has clinical practice. He is member of ASCPT, ACCP, SFTP, Club Phase I (actual president) and EUFEMED.

Jean-François ProstJean-François Prost

GamaMabs Pharma

Vice-President R&D and Strategy at GamaMabs Pharma

 Jean-François is a Senior Executive of the French and International pharmaceutical industry. Physician specialist in Internal Medicine, Dr. Prost has an experience of 30 years in the industry, having served as Cardiovascular Development Director then Research Director at Servier, R&D Director at Pierre Fabre Medicament and then UCB Pharma, and finally in the last ten years, Scientific and Medical Management at LFB. He’s today VP R&D and Strategy at GamaMabs Pharma company.

Jérôme TiollierJérôme Tiollier

Our Future Universe

Chairman, Co-founder, Our Future Universe

 

Jérôme TIOLLIER PhD, 60 years old, has been working since 35 years in pharmaceutical R&D with experience in senior leadership positions (ExCom), in ww pharma & biotech. Over-sight & management of multiple areas of drug development, including CMC, toxicology, PK, non-clinical, translational scientific research, clin-reg operations up to early (Phase I/II) clinical phases. Set overall department and project goals, timelines, resource and budgets, resulting in meeting corporate goals in a fast-paced environment. Responsible for strategy and implementation, ultimately accountable for the quality of the work and its interpretation. Initial background in cellular biology and preclinical & clinical development of “first in class” products in different medical and therapeutic field.

Latest position within INNATE PHARMA as EVP Chief Development Officer (2001-2018), member of the IPH ExCom, he participates to build the strategy and corporate achievement. In 2008, he started the US operations as President IPH Inc. and other corporate business development activities. Previously, he has been with IMEDEX (1986-1997) a French biotech spin off from Institut Mérieux where he managed different biological products from preclinical to early clinical stage (phase I/II) with the collaboration of internal R&D groups and CRO. Then he moves to Pasteur-Mérieux Transplant business unit (acquired by SANGSTAT in 1998, now part of Sanofi Genzyme,) as Preclinical Director (1997-1999) and European R&D Director (1999-2001). In the positions, he managed different pharmaceutical product license building as well as global research projects.  Graduated PhD with scientific background in cell biology and immunology.

In 2019 Jerome Tiollier starts with other seasoned managers of the industry a new venture of scientific media information website “sole in class” in the field: Our Future Universe (OFU).

Bernard VanhoveBernard Vanhove

Xenothera

Chief Operating Officer

Bernard Vanhove obtained his PhD from the University of Louvain (Belgium) and conducted an international academic and private carreer initiated at the Sandoz Vienna International Research Cooperation Centre (Austria) and at IMTIX-Sangstat (Lyon, France). He joined the CNRS (Centre National de Recherche Scientifique) in 1998 and became Research Director, working at the CRTI (Centre for Research in Transplantation and Immunology, Nantes, France). In 2013, Bernard Vanhove was awarded the « France Transplant » Prize for his work on the development of the first anti-CD28 antagonist antibody. He has been the coordinator of the European FP7 network « TRIAD » (Tolerance Restoration in Autoimmune Diseases) in autoimmune diseases. He authored about 100 international publications in the area of immuno-transplantation.
In 2008, Bernard Vanhove co-founded Effimune, becoming Chief Executive Officer, then Chief Operating Officer of OSE Immunotherapeutics untill 2019 when he became Chief Operating Officer of Xenothera (Nantes, France).

Hervé WatierHervé Watier

MAbImprove

Professor of Immunology at the Faculty of Medicine, Tours

Head of the Laboratory of Immunology in the University Hospital of Tours.

Hervé Watier is Professor of Immunology at the Faculty of Medicine, Tours, and Head of the Laboratory of Immunology in the University Hospital of Tours. Physician (MD) and scientist (PhD), he is working on the mechanisms of action of therapeutic antibodies in humans, which he contributed to discover through pharmacogenetic approaches. Since 2009, he is Director of the CNRS Research Network “Antibodies and therapeutic targeting”. He is also coordinating the laboratory of excellence (LabEx) “MAbImprove” since 2011 and a regional program dedicated to “Biopharmaceuticals” since 2013.

Nicolas PoirierNicolas Poirier

OSE Immunotherapeutics

Chief Scientific Officer

Nicolas Poirier earned his Ph.D. in Immunology at the European Center of Transplantation Sciences and Immunotherapy (CESTI) with guidance from immunotherapeutic-Transplant pioneer. He worked on the preclinical evaluation of novel therapeutic strategies modulating costimulation, immune checkpoint or complement pathways in preclinical models of transplantation and chronic inflammation. He received the awards “Prix de la Recherche Universitaire” by the French journal Le Monde and “New Key Opinion Leader” by the International Society of Transplantation. In 2009, he joined Effimune, a French biotechnology company specialized in immune regulation, as project manager and then he led R&D programs for 7 years. Upon the merger of Effimune with OSE pharma in 2016, he was appointed Chief Scientific Officer of OSE Immunotherapeutics, a leading biotechnology company in the field of immune activation and regulation with clinical applications in immuno-oncology, autoimmune diseases and transplantation. As CSO, he supported the company’s growth and his R&D team is interested in identification, evaluation and development of innovative immunotherapies to establish, break, regulate or reinforce immune regulation and activation.

Stephanie CornenStéphanie Cornen

Innate Pharma

Director, Research and development

Stéphanie Cornen joined Innate Pharma in May 2012 as R&D scientist in the Antibody Department. She became project manager in 2014 to work on the discovery of new first-in-class blocking antibodies. Since 2016, she leads the new target discovery program that aims to identify and validate new therapeutic targets in immuno-oncology. Stéphanie holds a PharmD and PhD in oncology (from Aix-Marseille University).

The COSSF’s mission is to contribute to the strategic scientific plans of action of MabDesign in the sector in order to foster innovation and economic development of companies as well as draft prospective reports on specific areas of the sector twice per year.

 

This is a unique website which will require a more modern browser to work!

Please upgrade today!